SunTrust Banks, Inc. restated their buy rating on shares of Boston Scientific Corporation (NYSE:BSX) in a report issued on Monday morning. They currently have a $34.00 price objective on the medical equipment provider’s stock.

Other analysts have also issued research reports about the stock. J P Morgan Chase & Co reiterated an overweight rating and issued a $31.00 target price (up previously from $27.00) on shares of Boston Scientific Corporation in a research report on Wednesday, June 28th. Royal Bank Of Canada reiterated a buy rating and issued a $31.00 target price on shares of Boston Scientific Corporation in a research report on Wednesday, July 12th. Wells Fargo & Company reiterated an outperform rating and issued a $31.00 target price (up previously from $29.50) on shares of Boston Scientific Corporation in a research report on Friday, June 16th. Needham & Company LLC lifted their target price on shares of Boston Scientific Corporation from $30.00 to $32.00 and gave the company a buy rating in a research report on Thursday, June 22nd. Finally, Oppenheimer Holdings, Inc. reiterated a hold rating on shares of Boston Scientific Corporation in a research report on Wednesday, June 28th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Boston Scientific Corporation currently has an average rating of Buy and a consensus price target of $30.06.

Shares of Boston Scientific Corporation (NYSE BSX) opened at 29.24 on Monday. The stock has a market cap of $40.12 billion, a PE ratio of 52.31 and a beta of 1.09. The firm has a 50-day moving average of $28.14 and a 200 day moving average of $26.94. Boston Scientific Corporation has a 52 week low of $19.67 and a 52 week high of $29.50.

Boston Scientific Corporation (NYSE:BSX) last announced its earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The business had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same quarter last year, the business earned $0.27 earnings per share. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. On average, equities analysts forecast that Boston Scientific Corporation will post $1.26 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/boston-scientific-corporations-bsx-buy-rating-reiterated-at-suntrust-banks-inc/1609550.html.

In other Boston Scientific Corporation news, EVP Timothy A. Pratt sold 11,061 shares of Boston Scientific Corporation stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $29.24, for a total transaction of $323,423.64. Following the transaction, the executive vice president now directly owns 174,681 shares of the company’s stock, valued at $5,107,672.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP John Bradley Sorenson sold 7,900 shares of Boston Scientific Corporation stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $26.37, for a total transaction of $208,323.00. Following the transaction, the senior vice president now directly owns 21,680 shares in the company, valued at $571,701.60. The disclosure for this sale can be found here. Insiders have sold 276,318 shares of company stock worth $7,567,967 over the last ninety days. 0.74% of the stock is owned by insiders.

Hedge funds have recently modified their holdings of the business. Acrospire Investment Management LLC raised its stake in Boston Scientific Corporation by 157.3% during the second quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock worth $141,000 after purchasing an additional 3,100 shares during the period. Guardian Life Insurance Co. of America raised its stake in Boston Scientific Corporation by 0.9% during the first quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock worth $131,000 after purchasing an additional 49 shares during the period. Bronfman E.L. Rothschild L.P. raised its stake in Boston Scientific Corporation by 14.3% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 5,761 shares of the medical equipment provider’s stock worth $160,000 after purchasing an additional 720 shares during the period. San Francisco Sentry Investment Group CA purchased a new position in Boston Scientific Corporation during the second quarter worth about $191,000. Finally, Peddock Capital Advisors LLC purchased a new position in Boston Scientific Corporation during the second quarter worth about $201,000. 90.44% of the stock is currently owned by institutional investors.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.